Burt De Mill

Burt De Mill has taught undergraduates at the Rady School of Management since 2018. He is a 15-year veteran of the CLIA/CAP certified clinical diagnostics industry, with a distinguished track record of product launches and commercial success at numerous early stage companies. His background includes extensive work in the commercialization of LDT’s (Laboratory Developed Tests) for oncology, as well as autism and developmental delay in children. Mr. De Mill served as the Chief Commercial Officer at Lineagen, Inc., where he successfully directed the launch of FirstStepDx, a novel genetic test for autism and developmental delay in children.  As the Sr. Vice President, Sales & Marketing at Genoptix Medical Labs from 2005 to 2010,  Mr. De Mill scaled  revenues from $4M to $184M in five years, earning Genoptix a top spot on the Deloitte LLP "Fast 50" companies in North America, as well as a successful NASDAQ IPO in October 2007. He has also held senior management positions at Invitrogen (Thermo Fisher) and Amersham Biosciences (GE Health), managing sales, marketing, R&D, engineering, and technical support teams.

Education
B.S. Microbiology, University of Maryland, College Park

Industry Area
Marketing
Economics

Courses Taught
MGT 103 Product Marketing and Management
MGT 162 Negotiation
MGT 166 Business Ethics and Corporate Social Responsibility